BioSpace News Archive

Eloxx Pharmaceuticals, Inc. today reported its financial results for the three months ended September 30, 2022 and provided a business update.

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, announced results from a prospective, multicenter, single-arm study of adults living with type 2 diabetes who achieved improvement in all clinical endpoints with the use of the t:slim X2 insulin pump with Control-IQ technology.

vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes (T1D) today reported financial results for the third quarter ended September 30, 2022, and provided an update on recent corporate developments.

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that its third quarter 2022 conference call, originally scheduled for today, will now be held tomorrow (Friday, November 11, 2022) before market open.

HilleVax, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel vaccines, announced that it will participate in the Guggenheim Securities 4th Annual Immunology and Neurology Day and the Stifel Healthcare Conference.

Cipher Pharmaceuticals Inc. announced its financial and operating results for the three and nine month periods ended September 30, 2022.

IBEX Technologies Inc. reported its financial results for the fiscal year ended July 31, 2022.

Transcenta Holding Limited (“Transcenta”) (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that it has presented two scientific posters at the 37th Society for Immunotherapy of Cancer’s (SITC) Annual Meeting in Boston, MA, November 8-12, 2022.

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, reported its financial and operating results for the three and nine months ended September 30, 2022.

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, reported its financial results for the quarter ended September 30, 2022 and provided a pipeline update.